Your email has been successfully added to our mailing list.

×
0 0.121212121212121 0.0606060606060607 0.0606060606060607 0.0378787878787879 0.0303030303030303 -0.00106060606060611 -0.0606060606060607
Stock impact report

Dr. William Chey Highlights Unmet Medical Need of Lactose Intolerance and Potential for Phase 3 Drug Candidate RP-G28 in Expert Call Hosted by Ritter Pharmaceuticals

RITTER PHARMACEUTICALS (RTTR) 
Last ritter pharmaceuticals earnings: 8/14 05:11 pm Check Earnings Report
US:NASDAQ Investor Relations: ritterpharmaceuticals.com/investors
Company Research Source: GlobeNewswire
LOS ANGELES, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases (GI) with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today recaps remarks made by Dr. William Chey, Professor of Medicine, Director of the GI Physiology Laboratory, and Co-Director of the Michigan Bowel Control Program at the University of Michigan in an expert call hosted by the Company. The full transcript and audio replay of the call is available at: https://www.ritterpharmaceuticals.com/investors/events-presentations During the call, Dr. Chey discussed the prevalence of LI in the United States: approximately 40 million Americans are affected with LI, and roughly nine million are affected moderately to severely1. Dr. Chey di Show less Read more
Impact Snapshot
Event Time:
RTTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for RTTR alerts
Opt-in for
RTTR alerts

from News Quantified
Opt-in for
RTTR alerts

from News Quantified